Bleeding frequency and characteristics among hematologic malignancy inpatient rehabilitation patients with severe thrombocytopenia
To identify the frequency and characteristics of bleeding complications during acute inpatient rehabilitation of hematologic malignancy patients with severe thrombocytopenia.
Retrospective descriptive analysis.
Comprehensive cancer center acute inpatient rehabilitation unit.
Consecutive hematologic malignancy patients with a platelet count of less than or equal to 20,000/microliter (μL) on the day of acute inpatient rehabilitation admission from 1/1/2005 through 8/31/2016.
Medical records were retrospectively analyzed for demographic, laboratory, and medical data. Patients were rehabilitated using the institutional exercise guidelines for thrombocytopenic patients.
Main outcome measures
Bleeding events noted in the medical record.
Out of 135 acute inpatient rehabilitation admissions, 133 unique patients were analyzed with a total of 851 inpatient rehabilitation days. The mean platelet count was 14,000/μL on the day of admission and 22,000/μL over the course of the rehabilitation admission. There were 252 days of inpatient rehabilitation where patients had less than 10,000/μL platelets. A total of 97 bleeding events were documented in 77/135 (57%) admissions. Of the 97 bleeding events, 72 (74%), 14 (14%), and 11 (11%) were considered to be of low, medium, and high severity, respectively. There were 4/97 (4%) bleeding events that were highly likely attributable to physical activity but only 1/4 was considered high severity. Bleeding rates were .09, .08, .17, and .37 for > 20,000, 15–20,000, 10–15,000, and < 10,000/μL mean platelet counts respectively (p = .003). Forty-four percent of patients were transferred back to the primary acute care service with infection being the most common reason for transfer.
This study is the first to examine exercise-related bleeding complications during acute inpatient rehabilitation in severely thrombocytopenic hematologic cancer patients. Bleeding rates increased with lower platelet counts. However, using the exercise guidelines for severely thrombocytopenic patients, the risk of severe exercise-related bleeding events was low.
KeywordsThrombocytopenia Cancer Rehabilitation Physical activity Exercise
Compliance with ethical standards
The approval for this study was obtained from the institutional review board (IRB). A waiver of informed consent was granted by the IRB in compliance with federal and institutional guidelines.
Conflict of interest
The authors declare that they have no conflict of interest.
- 13.Tompkins J, Norris T, Levenhagen K, et al. (2017) Academy of acute care physical therapy task force on lab values. Laboratory Values Interpretation Resource Available at http://c.ymcdn.com/sites/www.acutept.org/resource/resmgr/docs/2017-Lab-Values-Resource.pdf. Accessed Sept 2017
- 16.Shin KY, Bishop M, Kendall D, Washington C, Yi A (2002) Bleeding complications after physical therapy in the thrombocytopenic patient. Multinational Association of Supportive Care in Cancer 14th International Symposium, Boston, Massachusetts, June, 2002Google Scholar
- 18.Center for Medicare & Medicaid Services, Inpatient Rehabilitation Therapy Services: Complying with documentation requirements. Accessed 5 Jul 2017. Available at: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/Inpatient_Rehab_Fact_Sheet_ICN905643.pdf
- 19.Klein JH (1990) Muscular hematomas: diagnosis and management. J Manip Physiol Ther 13:96–100Google Scholar
- 21.Bergenthal N, Will A, Streckmann F, Wolkewitz KD, Monsef I, Engert A, Elter T, Skoetz N (2014) Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev 11:CD009075Google Scholar
- 27.Frey PM, Méan M, Limacher A, Jaeger K, Beer HJ, Frauchiger B, Aschwanden M, Rodondi N, Righini M, Egloff M, Osterwalder J, Kucher N, Angelillo-Scherrer A, Husmann M, Banyai M, Matter CM, Aujesky D (2015) Physical activity and risk of bleeding in elderly patients taking anticoagulants. J Thromb Haemost 13(2):197–205CrossRefPubMedGoogle Scholar
- 28.National Cancer Institute, Division of Cancer Treatment & Diagnosis, NCI common toxicity criteria. Accessed 5 Jul 2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic.../ctcmanual_v4_10-4-99.pdf
- 31.Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, Mintz PD, O'Malley BA, Sesok-Pizzini DA, Shander A, Stack GE, Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, Tobian AA, AABB (2015) Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 162(3):205–213CrossRefPubMedGoogle Scholar
- 35.Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, PATCH Investigators (2016) Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 387(10038):2605–2613CrossRefPubMedGoogle Scholar